Returns Breakdown
| Return On Tangible Assets | (0.29) | |
| Return On Capital Employed | (0.25) | |
| Return On Assets | (0.25) | |
| Return On Equity | (0.33) |
Estimating TherapeuticsMD (USA Stocks:TXMD) price for July 2024.
 | By Rifka Kats | Macroaxis Story |
TherapeuticsMD has a beta of 0.7063, indicating its returns are highly responsive to market fluctuations. As the market swings, the company's returns are expected to correspondingly adjust. The beta metric assists investors in determining whether TherapeuticsMD's movements align with the broader market and its relative volatility or risk. Essentially, if TherapeuticsMD's deviation from the market is minimal, it adds little risk to an investment portfolio but also offers limited potential for increased returns.
Primary Takeaways
Investing in TherapeuticsMD (TXMD), a player in the Drug Manufacturers - Specialty & Generic industry, could potentially yield significant returns by July 2024. Despite a current open price of $1.92 and a slight price change of -$0.11, the stock's potential upside is estimated at 3.78, indicating a promising future for investors. However, it's important to note the company's negative market risk adjusted performance of -0.53 and a Treynor Ratio of -0.54, suggesting a higher level of risk. The stock's mean deviation stands at 1.72, further emphasizing the need for careful risk management in this investment.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
Every cloud has a silver lining, and this might just be the case for TherapeuticsMD (TXMD), a healthcare player in the pharmaceutical sector. As of June 24, 2024, TXMD's typical day price stands at $1.85, with a negative PEG ratio of 0.73, indicating a potential undervaluation. Despite a loss in the daily balance of power, Wall Street's target price is optimistic at $5, suggesting a possible upside of over 170%. However, the road to July 2024 might be a rocky one for TXMD, with a negative period momentum indicator of -0.11. It's a high-risk, high-reward scenario, and only time will tell if the company can turn the tides in its favor. Currently, TherapeuticsMD's Enterprise Value is anticipated to decrease significantly, based on recent years' reports. The Price-to-Book (Ptb) Ratio for this year is projected to rise to 0.84, while the Book Value Per Share is expected to drop to 2.66. This article aims to analyze TherapeuticsMD's potential for July, assessing whether the stock is reasonably priced entering the month.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as TherapeuticsMD. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for TherapeuticsMD
Watch out for price decline
Please consider monitoring TherapeuticsMD on a daily basis if you are holding a position in it. TherapeuticsMD is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as TherapeuticsMD stock to be traded above the $1 level to remain listed. If TherapeuticsMD stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is TherapeuticsMD's Liquidity
TherapeuticsMD financial leverage refers to using borrowed capital as a funding source to finance TherapeuticsMD ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. TherapeuticsMD financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to TherapeuticsMD's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of TherapeuticsMD's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between TherapeuticsMD's total debt and its cash.
TherapeuticsMD Gross Profit
TherapeuticsMD Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing TherapeuticsMD previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show TherapeuticsMD Gross Profit growth over the last 10 years. Please check TherapeuticsMD's gross profit and other fundamental indicators for more details.
Breaking it down
The latest dip in stock price created some momentum for shareholders as it was traded today as low as 1.81 and as high as 1.92 per share. The company executives have failed to build on market volatilities in May. However, diversifying your overall positions with TherapeuticsMD may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.35. The current volatility is consistent with the ongoing market swings in May 2024 as well as with TherapeuticsMD unsystematic, company-specific events.
As Benjamin Franklin once said, an investment in knowledge pays the best interest. With a Wall Street target price of $5, TherapeuticsMD (TXMD) stock presents a potential upside of 3.78 by July 2024. Despite a high probability of bankruptcy at 95.97%, the company's book value per share stands at 2.49X, indicating a solid intrinsic value. However, investors should be cautious as the company's return on equity is at a loss of 0.2, and the current liabilities stand at $10.67M. The pharmaceutical sector is known for its volatility, and TXMD is no exception with a standard deviation of 2.27, but with careful analysis and strategic planning, this stock could offer significant returns..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of TherapeuticsMD. Please refer to our Terms of Use for any information regarding our disclosure principles.